Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amicus Therapeutics (FOLD) Non-Current Deferred Tax Liability (2016 - 2022)

Amicus Therapeutics (FOLD) has disclosed Non-Current Deferred Tax Liability for 10 consecutive years, with $4.9 million as the latest value for Q4 2022.

  • For the quarter ending Q4 2022, Non-Current Deferred Tax Liability changed 0.18% year-over-year to $4.9 million, compared with a TTM value of $4.9 million through Dec 2022, changed 0.18%, and an annual FY2022 reading of $4.9 million, changed 0.18% over the prior year.
  • Non-Current Deferred Tax Liability was $4.9 million for Q4 2022 at Amicus Therapeutics, roughly flat from $4.9 million in the prior quarter.
  • Across five years, Non-Current Deferred Tax Liability topped out at $6.5 million in Q1 2018 and bottomed at $4.9 million in Q4 2020.
  • Average Non-Current Deferred Tax Liability over 5 years is $5.5 million, with a median of $5.1 million recorded in 2019.
  • The sharpest move saw Non-Current Deferred Tax Liability crashed 96.28% in 2018, then grew 0.69% in 2021.
  • Year by year, Non-Current Deferred Tax Liability stood at $6.5 million in 2018, then dropped by 21.87% to $5.1 million in 2019, then decreased by 3.07% to $4.9 million in 2020, then grew by 0.69% to $4.9 million in 2021, then increased by 0.18% to $4.9 million in 2022.
  • Business Quant data shows Non-Current Deferred Tax Liability for FOLD at $4.9 million in Q4 2022, $4.9 million in Q3 2022, and $4.9 million in Q2 2022.